Clinical Trials
18 trialsNCT02465060 2026-05-26
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04067336 2026-05-13
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
Kura Oncology, Inc.
Phase 1/2 Active not recruiting
NCT02970318 2026-05-11
A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL
Acerta Pharma BV
Phase 3 Active not recruiting
NCT03399799 2026-05-08
MonumenTAL-1
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT03625037 2026-05-05
EPCOREâ„¢ NHL-1
Genmab
Phase 1/2 Active not recruiting
NCT02003222 2026-05-01
Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT02048813 2026-05-01
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT04666038 2026-04-24
BRUIN CLL-321
Eli Lilly and Company
Phase 3 Active not recruiting
NCT03145181 2026-04-23
MajesTEC-1
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT04557098 2026-04-13
MajesTEC-1
Janssen Research & Development, LLC
Phase 2 Active not recruiting
NCT04971226 2026-04-06
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
Novartis
Phase 3 Active not recruiting
NCT03336333 2026-03-09
SEQUOIA
BeOne Medicines
Phase 3 Active not recruiting
NCT04657081 2025-12-08
Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML)
Taiho Oncology, Inc.
Phase 1/2 Active not recruiting
NCT03589326 2025-11-26
A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia
Takeda
Phase 3 Active not recruiting
NCT03173248 2025-11-10
AGILE
Servier
Phase 3 Active not recruiting
NCT04258943 2025-09-18
Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia
Children's Oncology Group
Phase 1/2 Active not recruiting
NCT02475681 2025-08-27
ElevateTN
Acerta Pharma BV
Phase 3 Active not recruiting
NCT03836261 2024-12-27
AMPLIFY
Acerta Pharma BV
Phase 3 Active not recruiting